Webinar | Women’s Nutrition: Nourishing Womanhood From Pregnancy To Menopause
11 September | 12 PM ET: Register Now

This Startup’s Blood Test Detects Cancer With 96% Sensitivity Across 15 Cancer Types

Asima Health Wants to Make Cancer Monitoring as Simple as a Blood Test

Authors

Research Analyst

Summarize this blog post with:

Cancer survivors often require years of monitoring to detect recurrence or the development of new cancers. However, frequent testing can be difficult because existing approaches may involve expensive imaging procedures, specialized laboratories, and repeated hospital visits. According to the AACR Cancer Progress Report 2026, approximately 18.6 million people in the United States were living with a history of cancer as of January 2025, and this number is expected to exceed 22 million by 2035. As the survivor population grows, there is an increasing need for accessible monitoring technologies that can identify possible signs of cancer without relying exclusively on complex diagnostic procedures.

Canadian biotechnology startup Asima Health is developing a blood-based multi-cancer detection platform that measures changes in the physical properties of circulating DNA rather than sequencing it. Its technology uses a lab-on-a-chip system to measure electrical impedance, potentially reducing the complexity and cost of cancer testing. In a 2025 study published in Lab on a Chip, the company’s Asima Rev technology achieved 96.4% sensitivity and 94% specificity using 216 clinical samples across 15 cancer types. The underlying assay delivered measurements in under five minutes, although routine clinical use will require further validation and product development.

GreyB spoke with Dr. Shalini Gupta, founder of Asima Health, to understand how the technology works and its potential role in cancer monitoring. In this exclusive conversation, Dr. Gupta explains how changes in DNA structure can reveal cancer-related signals, why the company chose electrical measurements over conventional sequencing, and the challenges of bringing an affordable cancer detection platform into local diagnostic laboratories.

This interview is part of GreyB’s Scouted series, where we speak with innovative startups developing technologies that address important industry challenges. These conversations explore how emerging solutions work, what makes them different, and their potential for real-world applications.

“The technology that we are developing is a really novel lab on a chip platform. That can allow cheaper, better, faster multi-cancer detection and monitoring.” 

         â€” Dr. Shalini Gupta

image

Dr. Shalini Gupta is the founder of Asima Health, a Canadian biotechnology startup based in the Toronto–Kitchener region of Ontario. She holds a PhD in chemical engineering from North Carolina State University, where she trained in colloid science, studying the physical behavior of particles and molecules. Her expertise in this field has shaped Asima Health’s approach to detecting cancer through changes in DNA structure rather than genetic sequencing.

Asima Health Uses DNA Impedance Measurements for Multi-Cancer Detection

Asima Health is developing a lab-on-a-chip platform for detecting cancer-related changes in cell-free DNA collected from blood samples. Its technology focuses on changes in DNA methylation, a chemical modification that can affect DNA’s physical behavior.

Rather than identifying individual mutations or determining the location of a tumor, the platform is designed to recognize broad cancer-associated signals that may be shared across different cancer types. Asima Health is initially focusing on cancer monitoring, particularly for survivors who need regular testing for possible recurrence.

The company plans to commercialize its technology through diagnostic laboratories rather than provide testing services directly to patients.

Here are the key highlights from our conversation.

Most advanced blood-based cancer tests rely on DNA sequencing. How does Asima Health detect cancer without examining individual genetic mutations?

Dr. Shalini: Most blood-based cancer detection technologies focus on finding specific mutations or chemical modifications in DNA. They often use next-generation sequencing, which can provide highly detailed information but also requires sophisticated equipment, specialized expertise, and complex data analysis.

We approach DNA differently. My background is in colloid science, where we study molecules and particles based on their physical and chemical behavior. Instead of treating DNA only as genetic information, we examine it as a molecule whose structure changes under different conditions.

Imagine DNA as a necklace made of many beads. Conventional sequencing looks at individual beads to identify changes. We look at how those changes affect the behavior of the entire necklace. Our technology induces measurable structural responses in DNA and uses an electrical chip to detect them. This allows us to identify cancer-associated changes without sequencing individual DNA bases.

Your technology targets DNA hypomethylation. How does that translate into a measurable electrical signal?

Dr. Shalini: DNA hypomethylation refers to the loss of methyl groups, which are small chemical groups attached to DNA. Researchers have known for decades that changes in DNA methylation are associated with cancer. These changes can occur across several cancer types, which makes them interesting for developing a broad detection test.

What we are investigating is how the loss of methyl groups affects the physical behavior of DNA. Methyl groups interact differently with water, so changes in their presence can alter how DNA molecules behave in a liquid environment.

Our proprietary process uses these chemical properties to produce measurable differences between DNA from cancer patients and healthy individuals. We then use an electrical impedance chip to detect those differences. Because we are measuring physical changes rather than individual mutations, we don’t need DNA amplification, specialized biological receptors, or complex sequencing-based analysis.

Your early studies reported approximately 96% sensitivity and 94% specificity. How reliable are these results, particularly for early-stage cancers?

Dr. Shalini: We have conducted preliminary testing using clinical samples obtained from biobanks in India, the United States, and Canada. We wanted to understand whether our technology could distinguish between samples from cancer patients and healthy individuals.

What we observed was encouraging. The electrical signals from healthy samples generally clustered separately from those associated with cancer, although there was some overlap. In our initial testing, we achieved approximately 96% sensitivity and 94% specificity. That means we correctly identified around 96% of the cancer samples and 94% of the healthy samples.

We also examined approximately 65 samples from patients with stage I or stage II cancers and observed more than 90% detection accuracy in that group. However, this is still early evidence. We need to conduct larger studies to understand how the technology performs across different patient populations, identify potential sources of interference, and establish its limitations before it can be used routinely in clinical practice.

Many cancer tests identify the location or type of tumor. What can Asima’s technology tell patients, and where are its limitations?

Dr. Shalini: Our test is designed to identify broad signals associated with cancer rather than locate a particular tumor or identify a specific genetic mutation. This is an important distinction because we are looking for changes shared across different cancer types.

For cancer survivors, that broad detection capability could be valuable. Someone treated for one type of cancer may later experience a recurrence, cancer spreading to another organ, or a second primary cancer. A test that looks for signals across multiple cancer types could potentially serve as an initial screening step before more targeted investigations.

However, our technology cannot currently tell patients which type of cancer they have or where it is located. It is also not designed to predict whether someone will develop cancer in the future. Our aim is to assess whether cancer-associated signals are present at the time of testing. If the test indicates a possible cancer signal, patients would still need confirmatory investigations, such as imaging or more specific molecular tests.

You have reported collaborations with Mayo Clinic and Moffitt Cancer Center. How are these partnerships helping validate the technology?

Dr. Shalini: We have been fortunate to build relationships with several established hospitals and research institutions. These partnerships are particularly valuable because access to high-quality clinical samples is essential for understanding how our technology performs.

For example, we are working with Moffitt Cancer Center in Florida, where researchers are supporting our work by providing clinical samples. We also have a paid pilot with Mayo Clinic in Minnesota. At Rush University Medical Center in Chicago, we have an ethically approved research study, although funding constraints have delayed its execution. We also have connections with Toronto General Hospital in Canada.

These relationships help us understand the clinical need for our technology and create opportunities for further validation. However, we are not yet ready to distribute our platform widely. We still need to develop the product further, conduct additional studies, and generate the evidence required for regulatory approval.

If Asima Health intends to make cancer monitoring more accessible, who will be your first customers, and how will the technology fit into existing laboratories?

Dr. Shalini: We want to remain a technology and product provider rather than become a diagnostic testing service ourselves. Our goal is to equip laboratories with the instruments and testing kits they need to perform cancer monitoring locally.

Our initial customers would be diagnostic laboratories that already serve cancer patients and are willing to validate our early prototypes. These could be smaller laboratories or larger diagnostic groups with sufficient testing capacity. We would provide the equipment and consumable kits, while the laboratories would perform the tests and deliver results to their patients.

Our longer-term vision is to make the technology available through local laboratory networks, including those that already offer home blood collection services. The advantage is that patients could access testing much closer to where they live. Instead of sending samples to highly centralized facilities, we want to make it possible for local laboratories to perform the analysis and provide results on the same day.

Your technology uses fewer processing steps than conventional sequencing-based tests. How could this simplify manufacturing and laboratory adoption?

Dr. Shalini: One of our biggest advantages is the relative simplicity of the process. Many existing molecular diagnostic technologies require several stages of sample preparation, amplification, sequencing, and computational analysis. Each additional step introduces complexity and potential sources of error.

Our approach is designed to minimize those requirements. We use a relatively simple chemical process followed by an electrical measurement. We don’t need DNA amplification, specialized biological receptors, or extensive bioinformatics pipelines. This could make the technology easier to standardize and operate in laboratories that don’t have highly specialized molecular testing capabilities.

We believe this simplicity could help us scale more quickly once we have sufficient funding and validation data. However, we still need to demonstrate that the performance observed in our early studies can be reproduced consistently across different laboratories, operators, and patient populations.

What challenges are you facing in bringing Asima Health’s cancer detection platform to market, and what are your next priorities?

Dr. Shalini: One of our biggest challenges has been securing funding for product development and clinical validation. Developing a regulated diagnostic platform requires substantial investment, particularly when the technology involves hardware and a measurement approach that investors may not immediately understand.

There is also skepticism surrounding new blood-based cancer tests. Several companies are already working in this space, and potential investors naturally want strong evidence that a new technology can perform reliably. We have promising preliminary data and support from clinical researchers, but we recognize that larger studies are necessary before we can make broader claims about performance.

Our next priorities are to refine the prototypes, expand clinical testing, understand potential sources of measurement interference, and build the evidence needed for regulatory review. We also need to establish reliable manufacturing and demonstrate that laboratories can reproduce our results. Ultimately, we want to make cancer monitoring more accessible so that patients can receive testing according to their clinical needs rather than being limited by the availability and cost of diagnostic infrastructure.

Meet our Interviewer –Shivangi Chadha, Research Analyst at GreyB

Shivangi Chadha

Shivangi Chadha, Research Analyst

Leveraging domain knowledge in F&B, biotech, and pharmacology to scout innovations and deliver actionable competitive and IP insights.

Share This Article:

Related Articles

Table of Contents

More Insights For You

Women Healthcare Research (1)

​Globally, women live on average five years longer than men, but spend more years in poor health. Closing this health gap represents a $1 trillion annual opportunity for the global

COPD research

The argument that biologics couldn’t work in COPD, that the disease was too heterogeneous, too poorly stratified, too unlike asthma, is now moot.  Three FDA approvals in under a year

This Startup Makes Human Skin with Hair Follicles and Sweat Glands to Reduce Animal Trials

Drug development often takes more than ten years and can cost over $2 billion per successful drug candidate. A major reason is that animal models often fail to accurately predict

upc opt outs

When the Unified Patent Court came into force in June 2023, the questions were procedural: how the court would operate, what unitary patent coverage would mean in practice, and how

This Startup Created a Portable Test That Could Replace Multi day UTI Lab Workflows

According to the Global Burden of Disease Study, cases of Urinary tract infections increased by more than 66% between 1990 and 2021. The problem is not just scale. Standard urine

AI drug discovery startups

If drug discovery is your bread and butter, you might already know that drug development often takes a decade of research and billions in investment before the drug reaches the

Facing A Roadblock On Your Project?

Our Experts Are Here To Help.